Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14398 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Shahrier Hossain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Melphalan, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Oncopeptides, Dana-Farber Cancer Institute.
Abstract (Originalsprache)
Objective
Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed/refractory multiple myeloma (RRMM) with ≥ 3 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real‐world setting.
Methods
In this retrospective analysis, we examined baseline features, efficacy, and safety outcomes with melflufen plus dexamethasone in a cohort of 12 patients with heavily pre‐treated RRMM at the Dana‐Farber Cancer Institute, USA.
Results
Patients had received a median of 5.5 prior lines of therapy. Three patients (25%) had extramedullary disease, three (25%) cytogenetically high‐risk features, and five (42%) had received prior autologous stem cell transplantation. The overall response rate was 55% (complete response: three [27%], very good partial response: one [9%], partial response: two [18%] patients). Five patients (42%) had stable disease; one was non‐evaluable. Adverse events (AEs) were mostly hematologic and proved manageable; two patients had Grade 2 infections. Reasons for melflufen discontinuation were progressive disease (42%), drug withdrawal from the United States market (33%), AEs (17%), and sudden death (8%) unrelated to treatment.
Conclusions
Consistent with clinical trial data, melflufen had an expected safety profile with manageable toxicity and clinically meaningful efficacy in patients with RRMM treated in the real‐world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
ORCID-Profile: Shahrier Hossain, Paul G Richardson
Förderung
- Oncopeptides
- Dana-Farber Cancer Institute
Zitieren
APA
Hossain, S., Mo, C., Patches, S., Leblebjian, H., Goodrich, K., Regan, E., O'Neill, K., Noonan, K., Richardson, P. G., & Laubach, J. (2025). Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma. European Journal of Haematology. https://doi.org/10.1111/ejh.14398
Vancouver
Hossain S, Mo C, Patches S, Leblebjian H, Goodrich K, Regan E, et al. Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma. European Journal of Haematology. 2025. doi:10.1111/ejh.14398
BibTeX
@article{Hossain2025,
author = {Hossain, Shahrier and Mo, Clifton and Patches, Sarah and Leblebjian, Houry and Goodrich, Kathryn and Regan, Eileen and O'Neill, Kathleen and Noonan, Kim and Richardson, Paul G and Laubach, Jacob},
title = {Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14398}
}
EUVIMED